Key regions: Australia, Japan, United States, Germany, Europe
The demand for Anti-Coagulants in Kenya has been on the rise in recent years.
Customer preferences: Anti-Coagulants are drugs that prevent blood clots, which can cause serious health problems such as deep vein thrombosis and stroke. These drugs are primarily used by patients with heart conditions, those who have undergone surgery, and those with a history of blood clots. In Kenya, there has been an increasing awareness of the importance of preventive healthcare, leading to a rise in demand for Anti-Coagulants.
Trends in the market: The Anti-Coagulants market in Kenya has been growing steadily in recent years. One of the key drivers of this growth is the increasing incidence of heart disease and stroke in the country. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death in Kenya, accounting for over 10% of all deaths. This has led to an increased demand for Anti-Coagulants, which are used to prevent and treat these conditions.Another trend in the Anti-Coagulants market in Kenya is the increasing availability of generic drugs. Generic drugs are cheaper than their branded counterparts and are becoming more widely available in the country. This has made Anti-Coagulants more affordable for patients, leading to an increase in demand.
Local special circumstances: Kenya has a large population of people with HIV/AIDS, and many of these individuals are at risk of developing blood clots. This has led to an increased demand for Anti-Coagulants among this population. Additionally, the country has a growing elderly population, who are more likely to develop conditions such as heart disease and stroke.
Underlying macroeconomic factors: Kenya's economy has been growing steadily in recent years, leading to an increase in disposable income among the population. This has made healthcare more accessible and affordable for many Kenyans, leading to an increase in demand for Anti-Coagulants. Additionally, the government has been investing in the healthcare sector, which has led to an increase in the availability of healthcare services and drugs in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
